Did you know? PROs are impacting treatment advances in metastatic breast cancer. Olaparib increased progression-free survival among BRCA carriers with metastatic HER2- breast cancer. Thanks to patient reported outcomes, a new study now suggests it also improved patients’ quality of life! Check it out the new article published in October 2019 directly at https://www.ncbi.nlm.nih.gov/pubmed/31446213!
Tag: Patient-reported Outcomes
Permanent link to this article: https://inheritedcancer.net/post12819/
Permanent link to this article: https://inheritedcancer.net/post12319/